10.15.24 -- Araris Doubles Down With Dual-payload ADC

By reducing the size of drug particles, nanoforming can open up new opportunities – from increasing bioavailability to enabling sustained drug delivery. Discover the potential benefits supported by case studies.

Discover a screening process to quickly assess HME feasibility that yields more accurate predictions for API loading and degradation while saving material and time compared to traditional approaches.

Find out how you can eliminate stability storage risks and save your resources and finances.

The path to regulatory approval for LNPs demands carefully considered strategies. By adopting strategic approaches, developers can overcome regulatory hurdles on the path to approval.

The paradigm shift from animal to human Organ-Chips in preclinical research offers promising insights and efficiencies, crucial for advancing drug development and reducing human suffering.

ADCs have emerged as a promising class of targeted cancer therapies. Explore linker-payload design elements, conjugation and characterization of ADCs, and the different bioassays used to screen ADCs.